Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003080
- Lead Sponsor
- Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;
2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;
3) Inpatients aged 18 to 75 years male or female;
4) Volunteer to receive treatment under their own scheme and sign informed consent.
1) Patients with mild, severe or critical novel coronavirus disease;
2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;
3) Those who are allergic to the research drug and its main ingredients;
4) pregnant or lactating women;
5) Those who have difficulty taking medicine orally.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.